appScorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Sun Pharmaceutical Industries Ltd
SUNPHARMA
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Analysts have suggested that investors can buy this stock
Company Profile
Sun Pharmaceutical Industries Limited is a pharmaceuticals company which offers generics, branded generics, specialty products, over-the-counter products, anti-retroviral and APIs.
Brands
Investor PresentationView older
View Older PresentationsBrands
PeersCompare with peers
Zydus Lifesciences Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
Bulls back on D-Street: Investors gain Rs 7 lakh crore as Sensex, Nifty rebound
11 hours ago•Business Today
Cipla, Divi’s Labs Lead Pharma Stocks Rally To New High
12 hours ago•Bloomberg Quint
Sun Pharma receives USFDA approval for LEQSELVI (deuruxolitinib) 8 mg tablets
14 hours ago•Business Standard
Recent EventsAll events
Press Release
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated July 26, 2024, titled "Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 U.S. FDA Approves LEQSELVI (deuruxolitinib)". | Download
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated July 26, 2024, titled "Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 U.S. FDA Approves LEQSELVI (deuruxolitinib)". | Download
Cash Dividend
Final • Div/Share: ₹ 5
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant